Keynote 407 trial#
Objective To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC.ĭesign, Setting, and Participants This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. Importance This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non–small-cell lung cancer (sq-NSCLC). Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study. Tislelizumab-A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. In consequence, non-smokers patients need to are represented in clinical trials.ġ. For instance, if we think that around 10-15% of lung cancer patients in Western countries have never smoked.3 This kind of cancer represents an important public health problem in this population. Probably, due to these populations are underrepresented in this clinical trial. Especially, because another’s characteristics of the study were that in all the variables where the sample size is smaller, or where patients with tumors unevaluable for PD-L1 expression were included (<1% TC PD-L1 expression group), the results are inconclusive. Osarogiagbon that Tislelizumab is a promising new option for enhancing chemotherapy benefit in treatment for advanced sq-NSCLC,2 but more studies need to performance known the efficacy of this drug in different clinical scenarios. It is seeming that results could only be replicated in male patients, population under 65 years of age, patients with "1" ECOG performance status, smokers, and patients without liver metastasis. Were the same tolerability, efficacy and safety results obtained in patients with acute and chronic bronchopneumonia? Were there patients with acute and chronic bronchopneumonia? How were the results observed in patients with metastases to bone and brain? Were there patients with confirmed metastases in two or three different sites? Moreover, the authors did not show data for patients with bone and brain metastasis. In this type of patients, it could be assumed that they are subjected to other prognostic factors different from the ones being studied. Mainly when it comes to studying potentially causal associations between a certain exposure and an effect or outcome, such as for the analysis of the progression of the disease shown in this study. Therefore, it is of interest to know what prognostic factors influence the survival of this type of patient. The results have selection bias for female patients, patients with "0" ECOG (Eastern Cooperative Oncology Group) performance status, non-smokers, older adults (≥65 y), and patients with liver metastasis. Wang et al show results that suggest the addition of tislelizumab to standard chemotherapy represents an additional treatment option as first-line treatment for patients with advanced squamous non–small-cell lung cancer (sq-NSCLC).1 However, for some variables, the results are limited by their own study design. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Incidence of treatment-related adverse events occurring in ≥15% of patients Overall summary of treatment emergent adverse eventsĮTable 7. Biomarker interaction analysis for PD-L1 at cutoff of 1% TC per RECIST version 1.1 by independent review committee in ITT analysis setĮTable 6. Progression-free survival by PD-L1 per RECIST version 1.1 by independent review committee in ITT analysis setĮTable 5. Progression-free survival by disease stage per RECIST version 1.1 by independent review committee in ITT analysis setĮTable 4. Progression-free survival by independent review committee in patients with 2 patients across treatment armsĮTable 1. Progression-free survival by independent review committee in patients with 1-49% tumor cell PD-L1 expressionĮFigure 5. Progression-free survival by independent review committee in patients with ≥50% tumor cell PD-L1 expressionĮFigure 4. Progression-free survival by investigatorĮFigure 3. Criteria and end point defintionsĮFigure 2.
0 kommentar(er)
